Loss of AMP-Activated Protein Kinase-α2 Impairs the Insulin-Sensitizing Effect of Calorie Restriction in Skeletal Muscle

Pei Wang,1 Ruo-Yu Zhang,1 Jie Song,1 Yun-Feng Guan,1 Tian-Ying Xu,1 Hui Du,1 Benoit Viollet,2,3 and Chao-Yu Miao1

Wiehter the well-known metabolic switch AMP-activated protein kinase (AMPK) is involved in the insulin-sensitizing effect of calorie restriction (CR) is unclear. In this study, we investigated the role of AMPK in the insulin-sensitizing effect of CR in skeletal muscle. Wild-type (WT) and AMPK-α2−/− mice received ad libitum (AL) or CR (8 weeks at 60% of AL) feeding. CR increased the protein level of AMPK-α2 and phosphorylation of AMPK-α2. In WT and AMPK-α2−/− mice, CR induced comparable changes of body weight, fat pad weight, serum triglycerides, serum nonesterified fatty acids, and serum leptin levels. However, decreasing levels of fasting/fed insulin and fed glucose were observed in WT mice but not in AMPK-α2−/− mice. Moreover, CR-induced improvements of whole-body insulin sensitivity (evidenced by metabolic disorders (2 diabetes.diabetesjournals.org DIABETES 1)

This article contains Supplementary Data online at http://diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1180/-/DC1. DOI: 10.2337/db11-1180

Corresponding author: Chao-Yu Miao, cymiao@smmu.edu.cn or Pei Wang, p wang@smmu.edu.cn.

Received 23 August 2011 and accepted 18 January 2012.

From the 1Department of Pharmacology, Second Military Medical University, Shanghai, China; the 2Institut Cochin, Université Paris Descartes, Centre National de la Recherche Scientifique (Unité Mixte de Recherche 8104), Paris, France; and 3INSERM U1016, Paris, France.

Calorie restriction (CR) with adequate nutrition has been shown to improve age-related diseases and to slow the aging process (1). Moreover, CR results in weight loss and improvement for metabolic disorders (2–4). Many experimental and clinical studies show that insulin sensitivity is significantly improved by CR (5–7). CR could modulate insulin receptor (IR)/insulin-like growth factor I (IGF-I) receptor (IGF-IR) signaling (i.e., serum insulin/IGF-I levels) (8), IR substrate (IRS)-1 phosphorylation (9), and IRS-associated PI 3-kinase–Akt activity (10).

The AMP-activated protein kinase (AMPK) is a member of the SNF1/AMPK protein kinase family and serves as an energy sensor in all eukaryotic cells (11,12). It consists of one catalytic subunit (α) and two regulatory subunits (β and γ) (11,12). Upon activation by AMP (11,12) and ADP (13), AMPK shuts down anabolic pathways, such as synthesis of fatty acid, triglyceride, and cholesterol as well as transcriptional processes, and promotes catabolic pathways. AMPK has been shown to influence insulin sensitivity under both normal and high-fat diet (14–16) and can be activated by CR (17,18). The metabolic effects of resveratrol, a well-known CR mimetic compound, recently were found to require AMPK (14). On the basis of the findings summarized above, we speculate that CR could improve insulin sensitivity by activating AMPK. Moreover, in a very recent review, Cantó and Auwerx (19) proposed that AMPK is a key sensor or effector in CR-induced beneficial effects. Here, we demonstrate that AMPK is a primary sensor that controls insulin sensitivity upon CR in skeletal muscle through regulating phosphorylation of the mammalian target of rapamycin (mTOR)–S6K1–IRS-1 signaling pathway and activation of the nicotinamide phosphoribosyltransferase (Nampt)-sirtuin (SIRT1) axis.
**AMPK AND THE INSULIN-SENSITIZING EFFECT OF CR**

**Measurement of metabolic parameters.** Body weight was recorded every week. At the end of CR treatment, mice were anesthetized with phenobarbital sodium (35 mg/kg) and epididymal fat was isolated and weighed. Blood was collected from the heart and clotted to clot and then centrifuged for 20 min at 2,500 rpm. The serum (NEFA) concentration in serum was measured with the use of a NEFA-C test (Wako, Osaka, Japan). Serum adiponectin and leptin levels were measured with ELISA kits (R&D Systems, Minneapolis, MN). Serum insulin concentration was determined by ELISA (Linco). Serum lipid and glucose levels were measured using a Beckman biomedical autoanalyzer (Beckman Instruments, Brea, CA).

**Glycolytic and mitochondrial fluxes.** Glucose uptake in skeletal muscle tissue. The effect of AMPK-α2−/− mice was incubated at 37°C for 30 min in oxygenated (95% O2 + 5% CO2) Krebs-Henseleit buffer containing 0.5% BSA, 2 mMol/L sodium pyruvate, and 6 mMol/L mannitol for 10 min prior to 30-min insulin exposure (0.8 mMol/L) followed by 15-min 2-NBDG (50 μMOL/L) incubation. The specimens were thawed on filter paper, trimmed, and extracted using a lysis buffer. The amount of 2-NBDG in skeletal muscle was determined using a microplate fluorimeter (Infinite M200; Tecan, Hillsshore, NC) as previously described (22).

**Cell culture and transfection.** Mouse 2C12 myoblasts were purchased from American Type Culture Collection and cultured with Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) FBS, 2 mMol/L glutamate, 15 mMol/L NaHCO3, 10 mMol/L HEPES, 50IU/mL penicillin, and 100 μg/mL streptomycin and 0.5% (v/v) horse serum for 4 additional days. Transfection of small interfering (si)RNA was performed as described previously (23) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). siRNAs targeting X chromosome-linked ubiquitin-specific protease (USP) a (USP31), USP5, and USP7 were purchased from Santa Cruz Biotechnology. Flow cytometry was performed using 70–80% transfection efficiency.

**Immunoblotting.** Immunoblotting experiments on extracts of skeletal muscle or cell extracts were performed using Odyssey Infrared Fluorescent Imaging System (LI-COR Biosciences, Lincoln, NE) as described previously (20,24). Samples were homogenized with a lysis buffer (Pierce, Rockford, IL) containing a protease inhibitor cocktail (Pierce). Samples were subjected to 10–12% SDS-PAGE, electrotransferred to nitrocellulose membranes, probed with a primary antibody overnight, and then incubated with an appropriate secondary antibody conjugated with infrared dyes 800 and 680 (LI-COR Biosciences). All immunoblotting experiments were repeated at least three times.

**Phosphatase assay.** Phosphatase activity was assayed using a nonradioactive Ser/Thr phosphorylation assay using a protocol containing a protease inhibitor cocktail (Pierce). Samples were subjected to 10–12% SDS-PAGE, electrotransferred to nitrocellulose membranes, probed with a primary antibody overnight, and then incubated with an appropriate secondary antibody conjugated with infrared dyes 800 and 680 (LI-COR Biosciences). All immunoblotting experiments were repeated at least three times.

**RESULTS**

CR activates AMPK signaling pathway and increases the protein level of AMPK-α2. At first, we studied the activation of AMPK signaling pathway during CR. CR activated AMPK signaling pathway in skeletal muscle (Fig. 1A), evidenced by enhanced phosphorylation of Thr172 of AMPK-α2 and phosphorylation of acetyl CoA carboxylase (ACC), a downstream target of AMPK (Fig. 1B).

Quantitative PCR revealed higher mRNA level of the AMPK-α2 subunit (>10-fold vs. AMPK-α1 subunit) (Supplementary Fig. 1A) in mouse skeletal muscle. CR increased AMPK-α2 protein (Fig. 1C) but not AMPK-α1 protein (Supplementary Fig. 1B). Thr phosphorylation of AMPK-α2 was also significantly increased by CR (Fig. 1D).

On the basis of these findings, we focused on the role of AMPK-α2 in the CR-induced insulin-sensitizing effect in skeletal muscle in the next set of experiments.

**Influence of AMPK-α2 knockout on whole-body characterizations in mice upon CR.** After 8 weeks of AL and CR treatment, whole-body characterizations were monitored in WT and AMPK-α2−/− mice. Body weight reduction induced by CR was comparable between WT and AMPK-α2−/− mice (Table 1). Consistent changes were also observed in epididymal fat weight. It is interesting that CR decreased serum fasting insulin levels in WT mice but not in AMPK-α2−/− mice. CR reduced fed glucose levels in WT mice but not in AMPK-α2−/− mice. CR induced a comparable decrease of serum triglyceride levels, enhancement of serum NEFAs, and decline of leptin levels in WT and AMPK-α2−/− mice. CR did not affect serum adiponectin levels in either WT or AMPK-α2−/− mice.

**CR-induced increase of whole-body insulin sensitivity and enhancement of glucose uptake in skeletal muscle requires AMPK-α2.** ITT assay revealed enhanced insulin sensitivity upon CR in WT mice (Fig. 2A) but not in AMPK-α2−/− mice (Fig. 2B). In GTT assay, we observed a consistent effect (Fig. 2C and D). Next, we studied the effect of AMPK-α2 deletion on insulin-induced glucose uptake in isolated skeletal muscle. Under basal condition, there were no differences among the four groups (Fig. 2E). However, under insulin stimulation, CR significantly increased the glucose uptake in WT mouse skeletal muscle but not in AMPK-α2−/− mouse skeletal muscle (Fig. 2F).

Loss of AMPK-α2 inhibits CR-induced IRS-1–Akt pathway activation. The disappearance of the insulin-sensitizing effect of CR in AMPK-α2−/− mice raises the possibility that ablation of AMPK-α2 could impair the insulin-related signaling pathways. We examined the phosphorylation of IR/IGF-IR. CR enhanced phosphorylation of IRβ/IGF-IRβ.
in WT mice in response to bolus insulin injection and produced comparable increase in IR-β/IGF-IR-β phosphorylation in AMPK-α2−/− mice (Supplementary Fig. 2).

We next tested the Tyr phosphorylation of IRS-1. Under basal condition, there was no apparent Tyr phosphorylation of IRS-1 (Fig. 3A). Under insulin stimulation, CR increased Tyr phosphorylation of IRS-1 in WT control mice but less so in AMPK-α2 knockout mice (Fig. 3A). CR-treated WT mice exhibited remarkable increase of phosphorylation of Akt (Fig. 3B), which was attenuated in AMPK-α2−/− mice (Fig. 3B).

**FIG. 1.** CR increases the protein level of AMPK-α2 subunit and phosphorylation of AMPK-α2. A and B: CR for 8 weeks increased the phosphorylation of AMPK and ACC, an AMPK target in skeletal muscle. C: CR increased total AMPK-α2 protein level. D: AMPK-α2 in skeletal muscle lysate was enriched by immunoprecipitation and then probed with an anti-phospho-Thr antibody to detect the Thr phosphorylation of AMPK-α2. *P < 0.05 vs. AL. n = 4–6 per group. IP, immunoprecipitation; IB, immunoblot.

### TABLE 1

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>AMPK-α2−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AL</td>
<td>CR</td>
</tr>
<tr>
<td><strong>Initial weight (g)</strong></td>
<td>23.6 ± 1.2</td>
<td>24.3 ± 1.1</td>
</tr>
<tr>
<td><strong>Final weight (g)</strong></td>
<td>30.4 ± 2.1</td>
<td>21.8 ± 1.5*</td>
</tr>
<tr>
<td><strong>Weight gain (g)</strong></td>
<td>6.8 ± 0.8</td>
<td>−2.5 ± 0.3*</td>
</tr>
<tr>
<td><strong>Epididymal fat weight (g)</strong></td>
<td>0.91 ± 0.35</td>
<td>0.06 ± 0.001*</td>
</tr>
</tbody>
</table>

**Serum metabolites**

<table>
<thead>
<tr>
<th></th>
<th>AL</th>
<th>CR</th>
<th>AL</th>
<th>CR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fasting insulin (ng/mL)</strong></td>
<td>0.67 ± 0.08</td>
<td>0.52 ± 0.05*</td>
<td>0.64 ± 0.06</td>
<td>0.62 ± 0.09</td>
</tr>
<tr>
<td><strong>Fed insulin (ng/mL)</strong></td>
<td>1.36 ± 0.2</td>
<td>0.92 ± 0.15*</td>
<td>1.13 ± 0.13†</td>
<td>1.10 ± 0.17†</td>
</tr>
<tr>
<td><strong>Fasting glucose (mmol/L)</strong></td>
<td>6.2 ± 0.7</td>
<td>6.0 ± 0.4</td>
<td>6.9 ± 0.7</td>
<td>6.4 ± 0.6</td>
</tr>
<tr>
<td><strong>Fed glucose (mmol/L)</strong></td>
<td>9.2 ± 1.1</td>
<td>8.1 ± 1.0*</td>
<td>11.6 ± 1.6†</td>
<td>11.2 ± 1.6†</td>
</tr>
<tr>
<td><strong>Triglycerides (mmol/L)</strong></td>
<td>0.74 ± 0.14</td>
<td>0.49 ± 0.07*</td>
<td>0.81 ± 0.16</td>
<td>0.52 ± 0.15*</td>
</tr>
<tr>
<td><strong>NEFAs (mEq/L)</strong></td>
<td>0.41 ± 0.08</td>
<td>0.65 ± 0.09*</td>
<td>0.49 ± 0.11</td>
<td>0.71 ± 0.13*</td>
</tr>
<tr>
<td><strong>Leptin (ng/mL)</strong></td>
<td>0.71 ± 0.11</td>
<td>0.57 ± 0.07*</td>
<td>0.73 ± 0.081</td>
<td>0.61 ± 0.05*</td>
</tr>
<tr>
<td><strong>Adiponectin (μg/mL)</strong></td>
<td>7.8 ± 1.6</td>
<td>8.1 ± 2.1</td>
<td>7.5 ± 1.8</td>
<td>7.7 ± 2.3</td>
</tr>
</tbody>
</table>

Data are means ± SE and were analyzed with two-way ANOVA (genotype × diet) followed by Tukey post hoc analysis. CR lasted for 8 weeks. *P < 0.05 vs. AL within genotype. †P < 0.05 knockout vs. AL within diet. n = 8 per group.
We further evaluated the phosphorylation of TBC1D1 and TBC1D4, two downstream targets of Akt and important regulators of insulin functions in skeletal muscle (28). CR increased phosphorylation of TBC1D1 (Fig. 3C) and TBC1D4 (Fig. 3D) upon insulin stimulation, which were reduced by deletion of AMPK-α2 (Fig. 3C and D).

Loss of AMPK-α2 counteracts the effects of CR on IRS-1 Tyr phosphorylation through mTOR-S6K1 signaling pathway. Since it has been reported that Tyr phosphorylation of IRS-1 is positively regulated by phosphorylation of IR/IGF-IR (29), which was not altered by deletion of AMPK-α2 as shown above, and
negatively regulated by Ser phosphorylation of IRS-1 (29), we speculated that lack of AMPK-α2 could affect Tyr phosphorylation of IRS-1 by modulating Ser phosphorylation of IRS-1. Thus, we analyzed four Ser sites (Ser1101, Ser636/639, Ser612, and Ser307) of IRS-1. CR decreased phosphorylation of IRS-1 at Ser1101, Ser636/639, and Ser612 but not at Ser307 (Fig. 4A and B). Loss of AMPK-α2 abrogated the decline of IRS-1 phosphorylation at Ser1101 and Ser636/639 but not at Ser612 (Fig. 4A and B), suggesting Ser1101 and Ser636/639 could be modulated by AMPK-α2 upon CR.

Phosphorylation of IRS-1 at Ser1101 and Ser636/639 has been reported to be regulated by the mTORC1-S6K1 pathway (30,31), while AMPK regulates phosphorylation of mTOR (11). We therefore examined the phosphorylation of the mTOR-S6K1 signal pathway. In WT mice, CR decreased the levels of phospho-S6K1, phospho-mTOR, and total mTOR (Fig. 4C and D). Such responses were absent in AMPK-α2−/− mice (Fig. 4C and D).

Loss of AMPK-α2 compromises the effects of CR on the Nampt-SIRT1 cascade. We next tested whether the ablation of AMPK-α2 affects the SIRT1 activation upon CR.
in skeletal muscle. CR increased SIRT1 protein level in both WT and AMPK-α2−/− mice (Fig. 5A). However, the AMPK-α2−/− mice exhibited less increase of SIRT1 activity upon CR (Fig. 5B). To further determine SIRT1 activity, we examined deacetylation of PGC-1α and FOXO1 by SIRT1. CR enhanced the deacetylation of PGC-1α and FOXO1 in WT mouse muscle and to a much lesser degree, in AMPK-α2−/− mice (Fig. 5C).

Since SIRT1 activity is largely controlled by the NAD⁺ level, which in turn is controlled by Nampt (32–34), we next studied the influences of deletion of AMPK-α2 on NAD⁺ level and Nampt. As shown in Fig. 5D, CR increased the NAD concentration in WT control mice and to a much lesser degree, in AMPK-α2 knockout mice. Nampt protein expression was upregulated by CR in WT mouse muscle (Fig. 5E), which was partly suppressed in AMPK-α2−/− mice (Fig. 5E).

CR upregulates AMPK-α2 though increasing protein stability of AMPK-α2. In line with the in vivo data, CR serum treatment increased the total AMPK-α2 and p-AMPK

FIG. 4. Loss of AMPK-α2 impairs the CR-induced modulation of Ser phosphorylation of IRS-1 and the mTORC1-S6K1 signal pathway. A and B: Effects of CR on four Ser phosphorylation sites (Ser1101, Ser636/639, Ser612, and Ser307) of IRS-1 in skeletal muscle. The decreases of Ser1101 and Ser636/639 phosphorylation of IRS-1 by CR were impaired in AMPK-α2−/− mice. C and D: Effects of CR on phosphorylation of mTOR-S6K1 signal pathway were blocked by deletion of AMPK-α2. *P < 0.05 vs. WT-AL, #P < 0.05 vs. WT-CR. n = 6 per group. α2KO, AMPK-α2 knockout mice.
levels in cultured C2C12 cells (Supplementary Fig. 3). However, the AMPK-α2 mRNA level of skeletal muscle was not affected by CR (Supplementary Fig. 4). This discrepancy suggests a likelihood of posttranslational regulation of AMPK-α2. First, we tested whether the increase in phospho-AMPK is due to changes in the upstream kinase of AMPK or the phosphatase of AMPK. CR serum did not affect phospho-LKB1 (Supplementary Fig. 5), the major upstream kinase of AMPK in skeletal muscle (35), or mRNA level and activity of PP2A and PP2C (Supplementary Fig. 6), two major phosphatases of AMPK (11), excluding the preceding possibilities.

Hence, we next examined whether CR affects AMPK-α2 protein stability. Treatment with MG132, a proteasome inhibitor, dramatically increased AMPK-α2 levels in C2C12 cells (Fig. 6A). Since polyubiquitylation can hamper the phosphorylation of AMPK and AMPK-related kinases (36), we tested whether CR could increase AMPK-α2 stability by modulating the ubiquitin-proteasome system. As shown in Fig. 6B, CR serum significantly decreased the amount of polyubiquitinated AMPK-α2 in C2C12 myotubes.

The protein stability of AMPK-α2 was evaluated by degradation curve of AMPK-α2 via blocking protein synthesis with CHX. The half-life of AMPK-α2 was increased significantly by

FIG. 5. Loss of AMPK-α2 compromises the CR-induced activation of Nampt-SIRT1 axis. A: The increase of SIRT1 protein expression by CR in muscle was not affected by loss of AMPK-α2. B: SIRT1 was enriched by immunoprecipitation and then subjected to an acetylation activity assay to determine the SIRT1 activity. The increase of SIRT1 activity in muscle of CR mice was blunted by deletion of AMPK-α2. C: PGC-1α and FOXO1 were immunoprecipitated and probed with anti–acetyl-Lys (Ac-Lys) to assess the acetylation of PGC-1α and FOXO1, which reflect the deacetylation ability of SIRT1. CR increased deacetylation of PGC-1α and FOXO1 in skeletal muscle in WT mice but not in AMPK-α2-/- mice. D: Effects of CR on the NAD+ level in skeletal muscle were suppressed in AMPK-α2-/- mice. E: The upregulation of Nampt protein by CR was attenuated by deletion of AMPK-α2. *P < 0.05, **P < 0.01 vs. AL; #P < 0.05 vs. WT. n = 6 per group. α2 KO, AMPK-α2 knockout mice; IP, immunoprecipitation; IB, immunoblot.
CR serum (12–14 h vs. 4–6 h in AL serum-treated cells) (Fig. 6C and D), indicating that AMPK-α2 protein stability is increased by CR.

**USP9X mediates the ubiquitylation-dependent degradation of AMPK-α2.** Knock down of USP9X, but not USP5 and USP7, with siRNA blocked the ubiquitylation-dependent degradation of AMPK-α2 (Fig. 7A). On the basis of all the data, we proposed a scheme for the critical role of AMPK-α2 in the regulation of the insulin-sensitizing effect of CR in skeletal muscle (Fig. 7B).

### DISCUSSION

In this study, CR induced comparable body weight loss in WT and AMPK-α2−/− mice. Effects of CR on the fat pad weight, serum fasting glucose, serum triglycerides, serum NEFAs, and serum leptin levels were also comparable between WT and AMPK-α2−/− mice. However, the beneficial effects of CR on fasting/fed insulin and fed glucose levels existed only in WT mice, suggesting that deletion of AMPK-α2 could impair the insulin-sensitizing effects of CR. GTTs and ITTs confirmed that the insulin-sensitizing effects of CR were abolished in AMPK-α2−/− mice. These in vivo experiments were carried out in mice and may not necessarily reflect the situation in skeletal muscle. The next set of experiments was carried out in skeletal muscle isolated from AMPK-α2 knockout mice versus WT control mice. The results demonstrated that CR increases glucose uptake in WT control skeletal muscle but not in muscle isolated from AMPK-α2−/− mice. Skeletal muscle, adipose, and liver are thought to be classical insulin target tissues. Although there is no consensus on which tissue is most important for insulin action associated with CR, skeletal muscle is considered to account for much of the systemic action of insulin (37). Consequently, we concluded that loss of AMPK-α2 impairs the insulin-sensitizing effect of CR in skeletal muscle.

In the following mechanism study, we found that genetic ablation of the AMPK-α2 largely attenuated the increase of IRS-1 Tyr phosphorylation upon CR. The insulin–IR–IRS-1–Akt signaling pathway critically regulates glucose metabolism (38). In our study, deletion of AMPK-α2 did not modulate phosphorylation of IR/IGF-IR. The assay of screening of IRS-1 Ser phosphorylation sites showed that deficiency of AMPK-α2 impaired the decreases of IRS-1 phosphorylation at Ser636/639 and Ser1101 induced by CR. The mTOR-S6K1 signaling pathway, which has been shown to enhance the IRS-1 phosphorylation at Ser636/639 and Ser1101 induced by CR. The mTOR-S6K1 signaling pathway, which has been shown to enhance the IRS-1 phosphorylation at Ser636/639 and Ser1101 (30,31,39), was also suppressed by CR in WT mice but not in AMPK-α2−/− mice. These data suggest that the disrupted inactivation of the mTOR-S6K1 signaling pathway contributes to the impaired insulin-sensitizing effects of CR in AMPK-α2−/− mice. The results also indicate that phosphorylation of IRS-1 may be more important than the
phosphorylation of IR/IGF-IR for the enhancement of insulin sensitivity during CR. Together with the abolished induction of CR on Akt and TBC1D1/TBC1D4 in AMPK-α2−/− mice, it is reasonable to conclude that the altered IRS-1 Ser phosphorylation is one of the key mechanisms by which CR regulates the IR–IRS-1–Akt signal pathway.

SIRT1 is widely believed to be mainly responsible for the benefits of CR (40). Recent studies indicate a critical role of AMPK in the extended life span induced by CR (41,42). We and others have previously demonstrated that Nampt is an important protector against various types of stress (20,43,44). Nampt has also been reported to be an important regulator in insulin secretion and glucose homeostasis (45). In this study, we demonstrated that AMPK activation by CR in the skeletal muscle precedes and determines the changes in Nampt expression, NAD+ level, and SIRT1 activity. The compromised SIRT1 activity in AMPK-α2−/− mice upon CR, in turn, abolished the CR-induced deacetylation of PGC-1α and FOXO1. Acetylation in the COOH-terminal region of the DNA binding domain of FOXO1 by p300 and cAMP-responsive element–binding protein and deacetylation by SIRTs greatly modulated FOXO regulatory function on glucose and lipid metabolism (46). In addition, reversible acetylation–deacetylation of PGC-1α is an important feature that contributes to the adaptation of mitochondrial energy homeostasis to changes in energy levels in insulin sensitivity regulation (47). These data suggest that under the CR condition, loss of AMPK-α2 effectively abrogates the increase of SIRT1 activity through inhibiting Nampt expression and NAD+ level and thereby makes Nampt the possible link between AMPK and SIRT1.

Results from the in vitro experiments suggested that USP9X mediates the ubiquitin-dependent degradation of AMPK-α2. Ubiquitination is a posttranslational modification that can rapidly alter protein function via proteasome-mediated degradation. It has been reported that the major metabolic effect of insulin in muscle is inhibition of protein degradation via the ubiquitin-proteasome system (9). Our findings support the hypothesis that one of the contributing mechanisms underlying the insulin-sensitizing effect of CR is secondary to changes in the ubiquitin-proteasome system in skeletal muscle. Because polyubiquitylation of AMPK has been shown to hamper the phosphorylation of AMPK (36), the inhibited polyubiquitylation of AMPK-α2 in C2C12 cells by CR serum would help to enable more AMPK-α2 protein to be phosphorylated/activated. It should be noted that the phosphorylation of AMPK-α2 was increased upon CR even after correcting by total AMPK-α2, suggesting ubiquitylation-independent mechanisms also participated in increased phosphorylation of AMPK-α2 by CR.

AMPK-α2 null mice on an AL diet are reported to be insulin resistant because of alteration in sympathetic

![FIG. 7. Knock down of USP9X, but not USP5 and USP7, blocks the ubiquitylation-mediated degradation of AMPK-α2. A: C2C12 myoblasts were transfected by siRNA-USP9X, siRNA-USP5, and siRNA-USP7 and then exposed to CHX for 12 h to block protein synthesis. AMPK-α2 protein levels in cells without and with CHX treatment (12 h) were determined by immunoblotting. Knock down of USP9X, but not USP5 and USP7, blocked the ubiquitylation-mediated degeneration of AMPK-α2. *P < 0.05 vs. without CHX treatment. B: Proposed scheme for the critical role of AMPK in the regulation of insulin-sensitizing effect of caloric restriction. AMPK-α2 plays a critical role in CR-induced insulin-sensitizing effect in skeletal muscle through regulating mTOR–S6K1–IRS-1 Ser phosphorylation and the Akt–TBC1D1/TBC1D4 signal pathway. AMPK-α2 is also required for the activation of the Nampt-NAD+–SIRT1 axis in skeletal muscle during caloric restriction. Ubi, ubiquitylation.](diabetes.diabetesjournals.org)
nervous activity (16). Whether the existed insulin resistance contributes to the lessened response to CR in AMPK-α2−/− mice is unknown, but the possibility exists. AMPK may influence the insulin-sensitizing effect of CR through both local and systemic action, which remains to be studied in the future. Also, the unknown serum factor(s) that mediate the CR-induced insulin-sensitizing action need to be identified in further studies.

In summary, we demonstrated that upregulation of AMPK-α2 is critical in the insulin-sensitizing effect of CR in skeletal muscle. We also showed that CR-induced AMPK-α2 upregulation in skeletal muscle is partly mediated by decreased polyubiquitylation of AMPK-α2. These data provide first evidence that the CR-induced insulin-sensitizing effect in skeletal muscle requires functional AMPK-α2 (Fig. 7B).

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (81100866 to P.W. and 81100361 to C.-Y.M.), the National Basic Research Program of China (2009CB521902 to C.-Y.M.), the Program of Shanghai Subject Chief Scientist (10XD1403300 to C.-Y.M.), the Shanghai ‘Shu Guang’ Project (10G19 to C.-Y.M.), and the Second Military Medical University Young Investigator Foundation (2010QN06 to P.W.).

No potential conflicts of interest relevant to this article were reported.

P.W. researched data and wrote the manuscript. R.-Y.Z., J.S., Y.-F.G., T.-Y.X., and H.D. researched data and reviewed the manuscript. C.-Y.M. designed the study and reviewed the manuscript. C.-Y.M. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

REFERENCES

5. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994;17:30–36
34. Ho et C, van der Veer E, Akawi O, Pickering JG. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett 2008;583:3081–3085